CRISPR Therapeutics AG (LTS:0VRQ) Cash Flow for Lease Financing : $0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is CRISPR Therapeutics AG Cash Flow for Lease Financing?

CRISPR Therapeutics AG's Cash Flow for Lease Financing for the three months ended in Mar. 2024 was $0.0 Mil. CRISPR Therapeutics AG's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 was $0.0 Mil.

Compared with last quarter ($0.0 Mil in Dec. 2023 ), CRISPR Therapeutics AG's Cash Flow for Lease Financing remained the same in Mar. 2024 ($0.0 Mil).

CRISPR Therapeutics AG Cash Flow for Lease Financing Historical Data

The historical data trend for CRISPR Therapeutics AG's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Cash Flow for Lease Financing Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow for Lease Financing

Get a 7-Day Free Trial

CRISPR Therapeutics AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow for Lease Financing	Get a 7-Day Free Trial															-	-	-	-	-

CRISPR Therapeutics AG Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.

Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

CRISPR Therapeutics AG Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (LTS:0VRQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » Cash Flow for Lease Financing

Comparable Companies

Traded in Other Exchanges

CRSP:USA CRSP:Mexico

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

CRISPR Therapeutics AG (LTS:0VRQ) Headlines

No Headlines